Small cell lung cancer transdifferentiation: not a negligible phenomenon.
1/5 보강
[PURPOSE OF REVIEW] Small cell lung cancer (SCLC), particularly its transdifferentiated form, is highly aggressive and has a poor prognosis.
APA
Horvath L, Boettiger K, et al. (2026). Small cell lung cancer transdifferentiation: not a negligible phenomenon.. Current opinion in oncology, 38(1), 39-46. https://doi.org/10.1097/CCO.0000000000001205
MLA
Horvath L, et al.. "Small cell lung cancer transdifferentiation: not a negligible phenomenon.." Current opinion in oncology, vol. 38, no. 1, 2026, pp. 39-46.
PMID
41263473 ↗
Abstract 한글 요약
[PURPOSE OF REVIEW] Small cell lung cancer (SCLC), particularly its transdifferentiated form, is highly aggressive and has a poor prognosis. The diagnosis of SCLC transdifferentiation is challenging, as repeat biopsies are often not clinically feasible and few noninvasive predictors of this neuroendocrine transformation have been identified to date.
[RECENT FINDINGS] Some retrospective studies and case reports have investigated this phenomenon. These studies indicate that it can occur in non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, or rearranged during transfection (RET) fusions, typically following treatment with tyrosine kinase inhibitors. However, it has also been observed in cases of EGFR-wild type NSCLC after immunotherapy or radiation therapy.
[SUMMARY] Several molecular mechanisms that can drive SCLC transdifferentiation have been identified. The treatment of transdifferentiated SCLC remains a significant challenge, although promising new strategies are currently under investigation. This review summarizes the current understanding of SCLC transdifferentiation.
[RECENT FINDINGS] Some retrospective studies and case reports have investigated this phenomenon. These studies indicate that it can occur in non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, or rearranged during transfection (RET) fusions, typically following treatment with tyrosine kinase inhibitors. However, it has also been observed in cases of EGFR-wild type NSCLC after immunotherapy or radiation therapy.
[SUMMARY] Several molecular mechanisms that can drive SCLC transdifferentiation have been identified. The treatment of transdifferentiated SCLC remains a significant challenge, although promising new strategies are currently under investigation. This review summarizes the current understanding of SCLC transdifferentiation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.